QUIDELORTHO CORP Current Liabilities
QUIDELORTHO CORP (QDEL) had Current Liabilities of $993.40 million as of 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-07
- 2026-06-28: Liabilities, Current $993.40M.
- 2026-03-29: Liabilities, Current $962.40M.
- 2025-12-28: Liabilities, Current $966.10M.
- 2025-09-28: Liabilities, Current $767.90M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-28 | $993.40M 10-Q · filed 2026-08-07 |
| 2026-03-29 | $962.40M 10-Q · filed 2026-05-06 |
| 2025-12-28 | $966.10M 10-Q · filed 2026-08-07 |
| 2025-09-28 | $767.90M 10-Q · filed 2025-11-06 |
| 2025-06-29 | $1.14B 10-Q · filed 2025-08-06 |
| 2025-03-30 | $1.05B 10-Q · filed 2025-05-08 |
| 2024-12-29 | $998.80M 10-K · filed 2026-02-19 |
| 2024-09-29 | $1.03B 10-Q · filed 2024-11-08 |
| 2024-06-30 | $932.40M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $779.80M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $833.80M 10-K · filed 2025-02-27 |
| 2023-10-01 | $860.00M 10-Q · filed 2023-11-02 |
| 2023-07-02 | $790.00M 10-Q · filed 2023-08-09 |
| 2023-04-02 | $907.80M 10-Q · filed 2023-05-04 |
| 2023-01-01 | $1.01B 10-K/A · filed 2024-08-01 |
| 2022-10-02 | $872.70M 10-Q · filed 2022-11-04 |
| 2022-07-03 | $900.00M 10-Q · filed 2022-08-05 |
| 2022-01-02 | $323.50M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |